RESUMEN
Parietaria judaica and P. officinalis are the two most common subspecies of the Parietaria genus. P. judaica and P. officinalis have exhibited cross-reactivity in previous studies. P. judaica pollen is the main cause of allergy in the Mediterranean area. It has been shown that a high percentage of patients sensitized to P. judaica with allergic rhinitis (AR) have an increased risk of developing asthma. The present study aimed to confirm the cross-reactivity between P. judaica and P. officinalis and to evaluate the use of a single P. officinalis extract in patients allergic to both subspecies as a preferable option for the diagnosis and treatment of allergy in a highly pollinated area of the Spanish Mediterranean coast. The present study was a single centre, observational cross-sectional study of adult patients diagnosed with AR and/or bronchial asthma who were sensitized to Parietaria pollen. A total of 24 patients were enrolled in the study and included in the analysis. Allergovit® immunotherapy extracts were selected for the study based on the protein content (P. officinalis pollen extract). The results of an in vitro ELISA revealed that 79.1% (n=19) of the patient sera were reactive to immunotherapy extracts. ELISA inhibition assay of the IgE binding to P. officinalis demonstrated inhibition values >70% in the sera of highly reactive patients, confirming the cross-reactivity between the two Parietaria subspecies. In addition, all patients enrolled in the study exhibited double skin positivity against P. judaica and P. officinalis extracts, as assessed by the skin prick test, further supporting the in vivo reactivity between the two subspecies. The present study demonstrated that P. judaica and P. officinalis pollen extracts were highly cross-reactive, and that a unique P. officinalis pollen extract may be used for the diagnosis and immunotherapy of patients allergic to Parietaria.
RESUMEN
Pollen forecasting models are a useful tool with which to predict episodes of type I allergenic risk and other environmental or biological processes. Parietaria is a wind-pollinated perennial herb that is responsible for many cases of severe pollinosis due to its high pollen production, the long persistence of the pollen grains in the atmosphere and the abundant presence of allergens in their cytoplasm and walls. The aim of this paper is to develop artificial neural networks (ANNs) to predict airborne Parietaria pollen concentrations in the northwestern part of Spain using a 19-year data set (1999-2017). The results show a significant increase in the length of time Parietaria pollen is in the air, as well as significant increases in the annual Parietaria pollen integral and mean daily maximum pollen value in the year. The Neural models show the ability to forecast airborne Parietaria pollen concentrations 1, 2, and 3 days ahead. A developed model with five input variables used to predict concentrations of airborne Parietaria pollen 1 day ahead shows determination coefficients between 0.618 and 0.652.
Asunto(s)
Parietaria , Rinitis Alérgica Estacional , Alérgenos , Humanos , Polen , EspañaRESUMEN
A recombinant hybrid composed of the two major allergens of the Parietaria pollen Par j 1 and Par j 2 has been generated by DNA recombinant technology (PjED). This hybrid was produced in E. coli at high levels of purity. Then, the engineered derivative has been combined with a synthetic polyaminoacidic derivative having a poly(hydroxyethyl)aspartamide (PHEA) backbone and bearing both butyryl groups (C4) and succinyl (S) moieties in the side chain (PHEA-C4-S). The allergen-copolymer nanoaggregate was characterized by means of DLS, zeta potential, electrophoretic mobility and atom force microscopy analysis displaying the formation of a stable complex. Its safety has been proved in vitro on a murine cell line, human erythrocytes and basophils. Moreover, the formation of the complex did not alter the ability of the allergens to cross-link surface bound specific IgE demonstrating that the combination of an engineered hybrid with a copolymer did not interfere with its biological activity suggesting its employment as potential vaccine against Parietaria-induced allergies.
Asunto(s)
Alérgenos/inmunología , Antígenos de Plantas/inmunología , Portadores de Fármacos , Hipersensibilidad/prevención & control , Nanopartículas , Péptidos/química , Proteínas de Plantas/inmunología , Vacunación , Vacunas Sintéticas/inmunología , Alérgenos/química , Alérgenos/toxicidad , Animales , Antígenos de Plantas/química , Antígenos de Plantas/toxicidad , Basófilos/efectos de los fármacos , Basófilos/inmunología , Línea Celular , Supervivencia Celular/efectos de los fármacos , Química Farmacéutica , Estabilidad de Medicamentos , Electroforesis , Hemólisis/efectos de los fármacos , Humanos , Hipersensibilidad/inmunología , Inmunoglobulina E/inmunología , Luz , Macrófagos/efectos de los fármacos , Macrófagos/patología , Ratones , Microscopía de Fuerza Atómica , Nanotecnología , Proteínas de Plantas/química , Proteínas de Plantas/toxicidad , Dispersión de Radiación , Tecnología Farmacéutica/métodos , Vacunas Sintéticas/química , Vacunas Sintéticas/toxicidadRESUMEN
Parietaria judaica pollen is one of the main sources of allergens in the Mediterranean area. Its allergenic composition has been studied in detail showing the presence of two major allergens (Par j 1 and Par j 2) and two minor allergens belonging to the profilin and calcium binding protein families of allergens (Par j 3 and Par j 4, respectively). Clinical reports support the hypothesis of a limited cross-reactivity between profilin from Parietaria and unrelated sources. We screened a P. judaica cDNA library to identify novel forms of profilins with allergenic activity. This strategy allowed us to isolate a 767 bp cDNA containing the information for a 131 amino acids protein with homology to profilins from unrelated sources greater than that observed with the already published Parietaria profilins. This profilin was expressed in Escherichia coli as a recombinant protein and its immunological prevalence was studied in a population of Parietaria allergic patients from Southern Europe. Immunoblotting analysis showed that the Parietaria profilin was recognized by IgE from 6.5% of the allergic population. Finally, a selected population of profilin allergic patients was enrolled to demonstrate the cross-reactivity of this novel variant with other profilins from grass and date palm. In conclusion, molecular cloning and immunological studies have allowed the isolation, expression and immunological characterization of a novel cross-reactive profilin allergen from P. judaica pollen named Par j 3.0201.